It not only enhances the recognition and activation of CD8+ T cells on tumor cells, but also improves the sensitivity of tumor cells to CD8+ T cell killing, which provides a new strategy to enhance the effect of tumor immunotherapy 233 (Figure 8A). The gene discussed is CD8A; the disease is neoplasm.